tiprankstipranks
Trending News
More News >

Casi Pharmaceuticals announces anticipated milestones

Anticipate FDA feedback on clinical hold for AMR in Q2, 2025. Target IND submission for Aplastic Anemia in Q2, 2025. Report the interim data from the ongoing ITP phase 1 study in mid-2025. Anticipate finalizing the equity transfer agreement regarding Precision Autoimmune Therapeutics in Q2 2025. Upon completion of this transaction, CASI will have the sole global ownership of all indications in CID-103.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue